PURPOSE: The purpose of this study was to evaluate the safety and feasibility of transarterial fiducial marker implantation for CyberKnife radiotherapy to treat locally advanced pancreatic cancer. MATERIALS AND METHODS: Fifteen pancreatic cancer patients were enrolled for transarterial marker implantation. Embolization platinum coils were implanted as a fiducial marker within 20 mm of the cancer edge, and preferably within 3 mm. The technical success of the implantation was defined as implantation of at least one fiducial marker within 20 mm of the target tumor. Irradiation was performed using the CyberKnife system. RESULTS: For 14 of 15 patients, transarterial implantation was successfully performed, and for 13 of 14 patients, the tracking marker was implanted within 3 mm of the cancer. Tracking instability was observed in two patients, but irradiation was accomplished in all 14 patients. No major complications caused by the implantation procedure were observed. The median overall survival after irradiation was 13.8 months, and the 1- and 2-years survival rates were 62.9% and 32.3%, respectively. CONCLUSION: Transarterial fiducial marker implantation for pancreatic cancer can be safely performed for tracking, and it will be a valuable alternative approach to percutaneous fiducial marker implantation.
PURPOSE: The purpose of this study was to evaluate the safety and feasibility of transarterial fiducial marker implantation for CyberKnife radiotherapy to treat locally advanced <span class="Disease">pancreatic cancer. MATERIALS AND METHODS: Fifteen pancreatic cancerpatients were enrolled for transarterial marker implantation. Embolization platinum coils were implanted as a fiducial marker within 20 mm of the cancer edge, and preferably within 3 mm. The technical success of the implantation was defined as implantation of at least one fiducial marker within 20 mm of the target tumor. Irradiation was performed using the CyberKnife system. RESULTS: For 14 of 15 patients, transarterial implantation was successfully performed, and for 13 of 14 patients, the tracking marker was implanted within 3 mm of the cancer. Tracking instability was observed in two patients, but irradiation was accomplished in all 14 patients. No major complications caused by the implantation procedure were observed. The median overall survival after irradiation was 13.8 months, and the 1- and 2-years survival rates were 62.9% and 32.3%, respectively. CONCLUSION: Transarterial fiducial marker implantation for pancreatic cancer can be safely performed for tracking, and it will be a valuable alternative approach to percutaneous fiducial marker implantation.
Authors: Kush Goyal; Douglas Einstein; Rafael A Ibarra; Min Yao; Charles Kunos; Rod Ellis; James Brindle; Deepjot Singh; Jeffrey Hardacre; Yuxia Zhang; Jeffrey Fabians; Gary Funkhouser; Mitchell Machtay; Juan R Sanabria Journal: J Surg Res Date: 2011-09-05 Impact factor: 2.192
Authors: Shalini Moningi; Avani S Dholakia; Siva P Raman; Amanda Blackford; John L Cameron; Dung T Le; Ana M C De Jesus-Acosta; Amy Hacker-Prietz; Lauren M Rosati; Ryan K Assadi; Shirl Dipasquale; Timothy M Pawlik; Lei Zheng; Matthew J Weiss; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman Journal: Ann Surg Oncol Date: 2015-01-07 Impact factor: 5.344
Authors: Michael K Sanders; Arthur J Moser; Asif Khalid; Kenneth E Fasanella; Herbert J Zeh; Steven Burton; Kevin McGrath Journal: Gastrointest Endosc Date: 2010-04-01 Impact factor: 9.427
Authors: Walter G Park; Brian M Yan; Devin Schellenberg; Jeff Kim; Daniel T Chang; Albert Koong; Cheryl Patalano; Jacques Van Dam Journal: Gastrointest Endosc Date: 2010-03 Impact factor: 9.427
Authors: Jean-Claude M Rwigema; Simul D Parikh; Dwight E Heron; Michael Howell; Herbert Zeh; A James Moser; Nathan Bahary; Annette Quinn; Steven A Burton Journal: Am J Clin Oncol Date: 2011-02 Impact factor: 2.339
Authors: Christoph G Trumm; Sophia M Häussler; Alexander Muacevic; Robert Stahl; Sebastian Stintzing; Philipp M Paprottka; Frederik Strobl; Tobias F Jakobs; Maximilian F Reiser; Ralf-Thorsten Hoffmann Journal: J Vasc Interv Radiol Date: 2014-02-12 Impact factor: 3.464